<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820947</url>
  </required_header>
  <id_info>
    <org_study_id>MDT18034</org_study_id>
    <nct_id>NCT03820947</nct_id>
  </id_info>
  <brief_title>VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial</brief_title>
  <official_title>Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early &amp; Advanced Stage Superficial Venous Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™&#xD;
      Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of&#xD;
      Early and Advanced Stage Superficial Venous Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed with two randomized studies and one single arm study.&#xD;
&#xD;
      Two randomized studies are for CEAP 2-5 subjects:&#xD;
&#xD;
        1. VenaSeal vs. Surgical Stripping Study (outside of the United States only)&#xD;
&#xD;
        2. VenaSeal vs. ETA Study&#xD;
&#xD;
      The single arm study is for CEAP 6 subjects with active venous leg ulcers (VLU):&#xD;
&#xD;
      1. VLU Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous treatment satisfaction questionnaire-early (VenousTSQe)(For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study)</measure>
    <time_frame>30 days</time_frame>
    <description>Peri-procedural patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous treatment satisfaction questionnaire- status (VenousTSQs) (For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study)</measure>
    <time_frame>30 days</time_frame>
    <description>Patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of target vein treated (For Randomized studies, VenaSeal vs. ETA and VenaSeal vs. Surgical Stripping Study)</measure>
    <time_frame>Index procedure</time_frame>
    <description>Elimination of clinically relevant superficial truncal disease in each target vein at the time of index procedure as measured by the percentage of target vein length successfully treated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to ulcer healing (For VLU study)</measure>
    <time_frame>Index procedure through 24 months</time_frame>
    <description>Time to ulcer healing, calculated through healing confirmation and verified by an independent core laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic closure of the primary target superficial truncal vein</measure>
    <time_frame>6 months</time_frame>
    <description>Measured via Duplex Ultrasound showing primary target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual primary target vein after surgical stripping procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to work</measure>
    <time_frame>Index procedure through 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic closure of primary target vein</measure>
    <time_frame>30 days, and 12, 24, 36, 48 and 60 months</time_frame>
    <description>Measured via Duplex Ultrasound showing primary target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual primary target vein after surgical stripping procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic closure of target vein</measure>
    <time_frame>30 days, and 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Measured via Duplex Ultrasound showing target vein closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual target vein after surgical stripping procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success of each target vein</measure>
    <time_frame>Index procedure</time_frame>
    <description>Measured via Duplex Ultrasound showing target vein (including primary target vein) closure along the entire treated vein segment with no discrete segments of patency exceeding 5 cm after VenaSeal™ system and ETA procedures, or the absence of refluxing or residual target vein after surgical stripping procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention of any target vein</measure>
    <time_frame>Index procedure through 60 months</time_frame>
    <description>Assessed via number of the target veins requiring retreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reintervention of any target vein</measure>
    <time_frame>Index procedure through 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) occurring in the target limb</measure>
    <time_frame>Index procedure through 12 months</time_frame>
    <description>Adverse events occurring in target limb, evaluated from index procedure through 12 months are hypersensitivity to VenaSeal™ adhesive, phlebitis, granuloma, endovenous glue induced thrombosis (EGIT) or endovenous heat induced thrombosis (EHIT), symptomatic deep vein thrombosis (DVT) events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional adverse events</measure>
    <time_frame>Index procedure through 60 months</time_frame>
    <description>Additional adverse events that will be evaluated through 60 months are symptomatic pulmonary embolism (PE) and serious adverse events (SAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and type of adjunctive treatment conducted</measure>
    <time_frame>Index procedure through 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of healthcare resources utilized for target limb venous reflux disease</measure>
    <time_frame>Index procedure through 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of healthcare resources utilized for adverse events</measure>
    <time_frame>Index procedure through 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU study only: Number of ulcer related healthcare resources utilized</measure>
    <time_frame>Index procedure through 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to normal activities</measure>
    <time_frame>Index procedure through 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-procedural and post-procedural pain</measure>
    <time_frame>Index procedure, and 7 days and 30 days</time_frame>
    <description>Determined by using numeric rating scale (NRS) with a scale of 0-10, with '0' indicating no pain and '10' indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in venous disease symptoms compared to baseline measured by the revised Venous Clinical Severity Score (rVCSS)</measure>
    <time_frame>7 and 30 days, and at 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>rVCSS score ranges from 0 to 30, with higher score indicating severe venous disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in venous disease symptoms compared to baseline as measured by subject self-reporting symptoms</measure>
    <time_frame>7 and 30 days, and at 6, 12, 24, 36, 48, and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aberdeen Varicose Vein Questionnaire (AVVQ) score compared to baseline</measure>
    <time_frame>30 days, and 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The total score ranges from 0-100 points, with '0' point indicating the best quality of life and '100' points indicating worst quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D-5L) compared to baseline</measure>
    <time_frame>30 days, and 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Items are scored on a 1-5 scale, 5 being a worse outcome. Each of the 5 dimensions are scored separately to obtain a 5-digit code which is converted into a standard value by country. Max &amp; min values vary by country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the 36-Item Short Form Health Survey (SF-36) compared to baseline</measure>
    <time_frame>30 days, and 6 and 12 months</time_frame>
    <description>The total score ranges from 0 to 100, with higher scores indicating better general health perception.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Venous Dependent Quality of Life (VenousDQoL) compared to baseline</measure>
    <time_frame>30 days, and 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Measured by 0-5 and 0-7 point (there are two scales in this questionnaire) Likert scale with higher score indicating worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider experience evaluating overall satisfaction with the procedure</measure>
    <time_frame>Index procedure</time_frame>
    <description>Measured by a 5 point Likert scale ranging from 0-5, with 5 indicating the best outcome (extremely satisfied with the treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU Study: Ulcer recurrence on the target limb</measure>
    <time_frame>Following ulcer healing through 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU study: Ulcer healing rate</measure>
    <time_frame>Index procedure through 24 months or until ulcer healing has been confirmed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU Study: Ulcer-free time</measure>
    <time_frame>Through 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU Study: Venous treatment satisfaction questionnaire-early (VenousTSQe)</measure>
    <time_frame>30 days</time_frame>
    <description>Peri-procedural patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU Study: Venous treatment satisfaction questionnaire- status (VenousTSQs)</measure>
    <time_frame>30 days</time_frame>
    <description>Patient satisfaction as measured by a validated, patient-centered venous treatment satisfaction questionnaire (VenousTSQs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For VLU Study: Percentage of target vein treated</measure>
    <time_frame>Index procedure</time_frame>
    <description>Elimination of clinically relevant superficial truncal disease in each target vein at the time of index procedure as measured by the percentage of target vein length successfully treated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">806</enrollment>
  <condition>Venous Reflux</condition>
  <arm_group>
    <arm_group_label>VenaSeal™ Closure System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endothermal Ablation (ETA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical Stripping</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VenaSeal™ Closure System VLU Study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VenaSeal™ Closure System</intervention_name>
    <description>The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.</description>
    <arm_group_label>VenaSeal™ Closure System</arm_group_label>
    <arm_group_label>VenaSeal™ Closure System VLU Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endothermal Ablation (ETA)</intervention_name>
    <description>ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.&#xD;
Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice.</description>
    <arm_group_label>Endothermal Ablation (ETA)</arm_group_label>
    <other_name>Endovenous laser ablation(EVLA)</other_name>
    <other_name>Radiofrequency ablation (RFA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Stripping</intervention_name>
    <description>Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.</description>
    <arm_group_label>Surgical Stripping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥18 years of age&#xD;
&#xD;
          2. Patient has venous reflux in superficial truncal vein(s) (e.g., GSV, SSV, accessory&#xD;
             saphenous veins) with CEAP 2 (symptomatic) or CEAP 3, 4a, 4b, 5, 6, appropriate for&#xD;
             treatment, as confirmed by DUS&#xD;
&#xD;
          3. Eligibility for treatment:&#xD;
&#xD;
               -  VenaSeal vs ETA Study: Patient is eligible for treatment with the VenaSeal™&#xD;
                  system and ETA&#xD;
&#xD;
               -  VenaSeal vs Surgical Stripping Study: Patient is eligible for treatment with the&#xD;
                  VenaSeal™ system and surgical stripping&#xD;
&#xD;
               -  VLU Study: patients should be eligible for treatment with the VenaSeal™ system&#xD;
&#xD;
          4. Treatable refluxing segment of target vein(s) 10 cm in length or longer&#xD;
&#xD;
          5. Patient has a target vein diameter of ≥3 mm throughout the intended treated segment of&#xD;
             the target vein as measured by DUS while patient is standing&#xD;
&#xD;
          6. Patient is willing and capable of complying with specified follow-up evaluations at&#xD;
             the specified times&#xD;
&#xD;
          7. Patient has an ability to understand the requirements of the study and to provide&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a known history of allergic sensitivities (including but not limited to&#xD;
             cyanoacrylate adhesives), or any other condition, which in the opinion of the&#xD;
             investigator may make the patient more susceptible to cyanoacrylate adhesive&#xD;
             hypersensitivity&#xD;
&#xD;
          2. Patient has known deep vein obstruction in the target limb, as identified by the&#xD;
             site's standard of care&#xD;
&#xD;
          3. Patient has abnormal pulse exam or ABI &lt;0.8&#xD;
&#xD;
          4. Patient has acute superficial thrombophlebitis&#xD;
&#xD;
          5. Patient requires any non-target vein treatments in the contralateral or ipsilateral&#xD;
             limb, or any other surgical procedure up tp 30 days pre-procedure and through 3 months&#xD;
             post-procedure&#xD;
&#xD;
          6. Patient has any co-morbid conditions, which in the investigator's opinion may&#xD;
             interfere with the patient's compliance with study visits and procedures, or may&#xD;
             confound interpretation of study data (e.g., congestive heart failure Class III and&#xD;
             IV, non-ambulatory patients, severe hepatic dysfunction, life expectancy &lt; 1 year)&#xD;
&#xD;
          7. IFU contraindications:&#xD;
&#xD;
               -  VenaSeal vs. ETA Study: Patient has VenaSeal™ system and/or ETA product's IFU&#xD;
                  contraindication(s)&#xD;
&#xD;
               -  VenaSeal vs Surgical Stripping Study: Patient has surgical stripping and/or&#xD;
                  VenaSeal™ system IFU contraindication(s)&#xD;
&#xD;
               -  VLU Study: Patient has VenaSeal™ system IFU contraindication(s)&#xD;
&#xD;
          8. Patient is non-ambulatory&#xD;
&#xD;
          9. Patient is a female of childbearing potential who may be pregnant or breastfeeding at&#xD;
             the time of the index procedure&#xD;
&#xD;
         10. Patient belongs to a vulnerable population per investigator's judgment or patient has&#xD;
             any kind of disorder that compromises his/her ability to give written informed consent&#xD;
             and/or to comply with study procedures&#xD;
&#xD;
         11. Patient is currently participating in an investigational drug or device study when the&#xD;
             data collected could be conflicting or biased due to participation in another study&#xD;
&#xD;
         12. Patient has documented or suspected (by a clinician) COVID-19 infection currently or&#xD;
             within the past 6 months.&#xD;
&#xD;
         13. VLU Study: Patient has target ulceration identified to be of non-venous etiology, as&#xD;
             confirmed by the independent core laboratory&#xD;
&#xD;
         14. VLU Study: Patient has target circumferential ulceration that cannot be captured in a&#xD;
             single photograph (any ulcer curvature around the leg that goes out of sight)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Gibson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lake Washington Vascular, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manjit Gohel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addenbrooke's Hospital, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salem Arefe</last_name>
    <phone>+1 7075413256</phone>
    <email>salem.arefe@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shital Patel</last_name>
    <phone>+1 7075413256</phone>
    <email>shital.r.patel@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yavapai Regional Medical Center</name>
      <address>
        <city>Prescott Valley</city>
        <state>Arizona</state>
        <zip>86314-2255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Kumar, MD</last_name>
      <phone>928-759-5890</phone>
      <email>AKumar@yrmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Lynn Bessette</last_name>
      <phone>+1 928-759-5890</phone>
      <email>lbessett@yrmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>PIMA Heart and Vascular</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Joshua Balderman</last_name>
      <phone>716-279-8105</phone>
      <email>joshua.balderman@pimaheart.com</email>
    </contact>
    <contact_backup>
      <last_name>Manuel Ortiz</last_name>
      <phone>716-279-8105</phone>
      <email>manuel.ortiz@pimaheartandvascular.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Valley Vascular Surgical Associates</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Leigh Ann O'Banion</last_name>
      <phone>559-499-6678</phone>
      <email>LeighAnn.O'banion@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Gutierrez</last_name>
      <phone>559-499-6678</phone>
      <email>Ashley.Gutierrez@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Central Valley Vein and Wound Care</name>
      <address>
        <city>Visalia</city>
        <state>California</state>
        <zip>93291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Attaran, MD</last_name>
      <phone>203-785-2063</phone>
      <email>robert.attaran@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Juan Carmona</last_name>
      <phone>+1 203-785-2063</phone>
      <email>juan.carmona@yale.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Misaki Kiguchi</last_name>
      <phone>202-877-0275</phone>
      <email>mk1866@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin Roberts</last_name>
      <email>br550@georgetown.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julianne Stoughton, MD</last_name>
      <phone>617-726-4957</phone>
      <email>jstoughton@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathyrn Nuzzolo, MD</last_name>
      <phone>+1 617-726-4957</phone>
      <email>knuzzolo@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian Hospital/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Neil Khilnani</last_name>
      <phone>212-746-6248</phone>
      <email>nmkhilna@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eileen Chang</last_name>
      <phone>212-746-6248</phone>
      <email>eic2002@med.cornell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OhioHealth Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Phillips, MD</last_name>
      <phone>614-566-1268</phone>
      <email>John.Phillips2@ohiohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Bliemeister</last_name>
      <phone>+1 614-566-1268</phone>
      <email>Amanda.Bliemeister@ohiohealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Orion Medical</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505-3165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karan Bhalla, MD</last_name>
      <phone>713-943-2800</phone>
      <email>karan.bhalla@orionmedical.net</email>
    </contact>
    <contact_backup>
      <last_name>Cherie Morrow</last_name>
      <phone>+1 713-943-2800</phone>
      <email>cherie.morrow@orionmedical.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004-4623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Gibson, MD</last_name>
      <phone>425-453-1772</phone>
      <email>drgibson@lkwv.com</email>
    </contact>
    <contact_backup>
      <last_name>Kim Glorieux</last_name>
      <phone>+1 425-453-1772</phone>
      <email>kimg@lkwv.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Pankaj Jha</last_name>
      <phone>+61 406 761 429</phone>
      <email>pankaj.jha@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Helen Rodgers</last_name>
      <phone>+61 413 804 294</phone>
      <email>helen.rodgers2@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Laurencia Villalba</last_name>
      <phone>+61 2 4211 0400</phone>
      <email>laurenciavillalba@live.com</email>
    </contact>
    <contact_backup>
      <last_name>Angela Muir</last_name>
      <phone>+61 2 4222 5000</phone>
      <email>angela.muir@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <state>DIjon Cedex</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Romaric Loffroy</last_name>
      <phone>+33-3-80-29-55-86</phone>
      <email>romaric.loffroy@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Hedi-Akari</last_name>
      <phone>+33-3-80-29-55-86</phone>
      <email>mohamed-hedi.akari@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique du Parc</name>
      <address>
        <city>Lyon</city>
        <zip>69006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Philippe Nicolini</last_name>
      <phone>+33472057900</phone>
      <email>romaric.loffroy@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nina Pronina</last_name>
      <phone>+33612457905</phone>
      <email>nina.pro@hotmail.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Nicolas Neaume</last_name>
      <phone>+33561161301</phone>
      <email>nneaume@clinique-pasteur.com</email>
    </contact>
    <contact_backup>
      <last_name>Cécile Jarlier</last_name>
      <phone>+33627346848</phone>
      <email>cjarlier@clinique-pasteur.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Praxis fur Innere Medizin und Gefäβkrankheiten</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Tobias Hirsch</last_name>
      <phone>+49345503303</phone>
      <email>Tobias.Hirsch@gefaessmedizin-hirsch.de</email>
    </contact>
    <contact_backup>
      <last_name>Christiane Knöfler</last_name>
      <phone>+49345503303</phone>
      <email>christiane.knoefler@gefaessmedizin-hirsch.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Seung-Kee Min</last_name>
      <phone>+82 10-7567-8821</phone>
      <email>skminmd@snuh.org</email>
    </contact>
    <contact_backup>
      <last_name>Kwang Woo Choi</last_name>
      <phone>+82 10-7567-8821</phone>
      <email>choikw0528@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Jang Yong Kim</last_name>
      <phone>+82-2-2258-6090</phone>
      <email>vascularkim@catholic.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Min Ju Choi</last_name>
      <phone>+82-2-2258-2877</phone>
      <email>lemonia1221@naver.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Woo Park, MD</last_name>
      <phone>+82 1095454135</phone>
      <email>20040017@kuh.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Eun Young Kim</last_name>
      <phone>+82 1095454135</phone>
      <email>uylovegod@naver.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Suk-Won Song</last_name>
      <phone>82-2-2019-3380</phone>
      <email>sevraphd@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Seo-A Sim</last_name>
      <phone>82-2-2019-2473</phone>
      <email>Hongsun0627@yuhs.ac</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rijnstate - Locatie Arnhem</name>
      <address>
        <city>Arnhem</city>
        <zip>6815</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Michel Reijnen</last_name>
      <phone>+88 005 7282</phone>
      <email>MReijnen@rijnstate.nl</email>
    </contact>
    <contact_backup>
      <last_name>Daphne van der Veen</last_name>
      <phone>+88 005 7282</phone>
      <email>dvanderveen@rijnstate.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Granada (Hospital Campus de la Salud)</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Luis M Salmerón</last_name>
      <phone>+34-958-895-427</phone>
      <email>lmsalmeron95@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Eli García Peñalver</last_name>
      <phone>+34-958-895-427</phone>
      <email>eligarpe28@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sanitas Hospital Universitario La Zarzuela</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Juan Fontcuberta</last_name>
      <phone>+34 629 88 92 53</phone>
      <email>jmfontcuberta@sanitas.es</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Manzano</last_name>
      <phone>+34 629 88 92 53</phone>
      <email>icarretero@sanitas.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital de Morges - Ensemble Hospitalier de la Côte</name>
      <address>
        <city>Morges</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Hervé Probst</last_name>
      <phone>+41216200220</phone>
      <email>herve.probst@ehc.vd.ch</email>
    </contact>
    <contact_backup>
      <last_name>Aude Pasche</last_name>
      <phone>+41791728726</phone>
      <email>aude.pasche@ehc.vd.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Manj Gohel</last_name>
      <phone>01223 217246</phone>
      <email>m.gohel@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Aileen Nacorda</last_name>
      <phone>01223 274143</phone>
      <email>aileen.nacorda@addenbrookes.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust - Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Alun Davies</last_name>
      <phone>0203 31 17309</phone>
      <email>a.h.davies@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Carr</last_name>
      <phone>0203 31 37347</phone>
      <email>caitlin.carr2@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous reflux</keyword>
  <keyword>Venous leg ulcer</keyword>
  <keyword>Varicose Veins</keyword>
  <keyword>Chronic Venous Insufficiency</keyword>
  <keyword>VenaSeal</keyword>
  <keyword>Endothermal Ablation</keyword>
  <keyword>Surgical Stripping</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Laser Ablation</keyword>
  <keyword>Great Saphenous Vein</keyword>
  <keyword>Small Saphenous Vein</keyword>
  <keyword>Anterior Accessory Saphenous Vein</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

